Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Ono Pharmaceutical partners U.S. Aitia on Gemini Digital Twin discovery

2 September 2026 · By · Wire by Fusion42

Published

2 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Japan

◆ Source

Read at jp.ibtimes.com →

◆ Verified

Fusion42 · 3 September 2026 · Fusion42 review

Ono Pharmaceutical has partnered with U.S.-based Aitia to use Aitia's REFS causal AI and Gemini Digital Twin models for neuroscience drug discovery, granting Ono exclusive global options to develop and commercialise new drug candidates.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You in drug discovery can no longer ignore AI that goes beyond correlations to causal insights. This partnership signals a practical route to new neurological targets that conventional platforms missed.

◆ Coverage

1 source · 2 Sep 2026

◆ Related on Wire

◆ Topics

Biotechpharma-ai-partnershipdigital-twincausal-aineurologydrug-discovery